GERN · Geron Corp
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on June 30, 2026 of $1.28 per share. |
Common Stock
|
6,103 |
| 2026-05-20 | Bir Dawn Carter |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
220,000 |
| 2026-05-20 | O'Farrell Elizabeth G. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
220,000 |
| 2026-05-20 | Molineaux Susan |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
220,000 |
| 2026-05-20 | McDonald John F |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
220,000 |
| 2026-05-20 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
220,000 |
| 2026-04-13 | Williams Timothy |
SVP & General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests as follows: 312,500 shares underlying the option will vest on October 13, 2026; and the remaining shares will vest over the following 42 months in equal installments, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
2,500,000 |
| 2026-04-13 | Williams Timothy |
SVP & General Counsel |
Other↑
|
No Securities Owned
|
0 |
| 2026-03-31 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on March 31, 2026 of $1.49 per share. |
Common Stock
|
5,243 |
| 2026-03-25 | Chinoporos Constantine |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-03-25 | Andrews Patricia S |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shall vest and become exercisable in three equal annual installments starting on March 25, 2027, subject to the Reporting Person's continuous service (as defined in the Issuer's 2018 Equity Incentive Plan) with the Issuer through each such vesting date. |
Stock Option (Right to Buy)
|
270,000 |
| 2026-03-25 | Chinoporos Constantine |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shall vest and become exercisable in three equal annual installments starting on March 25, 2027, subject to the Reporting Person's continuous service (as defined in the Issuer's 2018 Equity Incentive Plan) with the Issuer through each such vesting date. |
Stock Option (Right to Buy)
|
270,000 |
| 2026-03-25 | Andrews Patricia S |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-02-18 | ROBERTSON MICHELLE |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
Shares of common stock acquired upon the vesting of restricted stock units ("RSUs"). |
Common Stock
|
27,500 |
| 2026-02-18 | ROBERTSON MICHELLE |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the Reporting Person's applicable RSU agreement, and does not represent a discretionary sale by the Reporting Person. |
Common Stock
|
9,855 |
| 2026-02-18 | ROBERTSON MICHELLE |
Director |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Restricted Stock Units
|
27,500 |
| 2026-02-17 | ROBERTSON MICHELLE |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests in 48 equal monthly installments commencing on March 17, 2026, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
1,660,000 |
| 2026-02-17 | Eid Joseph |
SVP,Head Glob. Medical Affairs |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests in 48 equal monthly installments commencing on March 17, 2026, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
2,220,000 |
| 2025-12-31 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on December 31, 2025 of $1.32 per share. |
Common Stock
|
5,918 |
| 2025-10-20 | ElNawawi Ahmed |
EVP, Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest as follows: 375,000 shares on April 20, 2026, the remaining 2,625,000 shares in a series of 42 equal monthly installments commencing April 20, 2026, provided the optionee continues to provide services to the Company. |
Stock Option (right to buy)
|
3,000,000 |
| 2025-09-30 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2025 of $1.37 per share. |
Common Stock
|
5,702 |
| 2025-08-07 | Semerjian Harout |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest as follows: 875,000 shares on February 7, 2026, the remaining 6,125,000 shares in a series of 42 equal monthly installments commencing February 7, 2026, provided the optionee continues to provide services to the Company. |
Stock Option (right to buy)
|
7,000,000 |
| 2025-08-07 | Semerjian Harout |
Director, Chief Executive Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-08-07 | Semerjian Harout |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest as follows: 1,000,000 shares on August 7, 2026, the remaining 3,000,000 shares in a series of 36 equal monthly installments commencing August 7, 2026, provided the optionee continues to provide services to the Company. |
Stock Option (right to buy)
|
4,000,000 |
| 2025-06-30 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on June 30, 2025 of $1.41 per share. |
Common Stock
|
5,540 |
| 2025-05-21 | McDonald John F |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
180,000 |
| 2025-05-21 | Aggarwal Gaurav |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
180,000 |
| 2025-05-21 | Bir Dawn Carter |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
180,000 |
| 2025-05-21 | O'Farrell Elizabeth G. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
180,000 |
| 2025-05-21 | LAWLIS V BRYAN |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
180,000 |
| 2025-05-21 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
180,000 |
| 2025-05-21 | Molineaux Susan |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Stock Option (right to buy)
|
180,000 |
| 2025-05-09 | LAWLIS V BRYAN |
Director |
Buy↑
|
Common Stock
|
13,300 |
| 2025-03-31 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on March 31, 2025 of $1.59 per share. |
Common Stock
|
4,913 |
| 2025-02-27 | Samuels Scott Alan |
EVP, Chief Legal Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The reported transaction represents the open market purchase of 15,000 shares at an executed price of $1.61 per share. The number of securities reported reflects the open market purchase of 15,000 shares and acquisition on June 30, 2024 of 7,432 shares and on December 31, 2024 of 4,250 shares of Geron common stock pursuant to the Employee Stock. |
Common Stock
|
15,000 |
| 2025-02-27 | Ziegler James |
EVP, Chief Commercial Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The reported transaction represents the open market purchase of 100,000 shares at an executed price of $1.60 per share. |
Common Stock
|
100,000 |
| 2025-02-27 | SCARLETT JOHN A |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The reported transaction represents the open market purchase of 12,500 shares at an executed price of $1.765 per share. |
Common Stock
|
12,500 |
| 2025-02-18 | ROBERTSON MICHELLE |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on February 18, 2025 and vests in 48 consecutive equal monthly installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Stock Option (right to buy)
|
656,000 |
| 2025-02-18 | Samuels Scott Alan |
EVP, Chief Legal Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Restricted Stock Units
|
104,000 |
| 2025-02-18 | SCARLETT JOHN A |
Director |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Restricted Stock Units
|
410,000 |
| 2025-02-18 | GRETHLEIN ANDREW J |
EVP, Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on February 18, 2025 and vests in 48 consecutive equal monthly installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Stock Option (right to buy)
|
839,000 |
| 2025-02-18 | SCARLETT JOHN A |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on February 18, 2025 and vests in 48 consecutive equal monthly installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Stock Option (right to buy)
|
2,457,000 |
| 2025-02-18 | GRETHLEIN ANDREW J |
EVP, Chief Operating Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Restricted Stock Units
|
140,000 |
| 2025-02-18 | ROBERTSON MICHELLE |
Director |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Restricted Stock Units
|
110,000 |
| 2025-02-18 | Samuels Scott Alan |
EVP, Chief Legal Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on February 18, 2025 and vests in 48 consecutive equal monthly installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Stock Option (right to buy)
|
621,000 |
| 2025-02-18 | Ziegler James |
EVP, Chief Commercial Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Restricted Stock Units
|
89,000 |
| 2025-02-18 | Ziegler James |
EVP, Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on February 18, 2025 and vests as to 1/8th of the shares underlying the option on the sixth-month anniversary of the Reporting Person's date of hire of September 9, 2024, and as to the remaining shares underlying the option in 42 consecutive equal monthly installments thereafter, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. |
Stock Option (right to buy)
|
529,000 |
| 2024-12-31 | Spiegel Robert J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on December 31, 2024 of $3.54 per share. |
Common Stock
|
2,206 |
| 2024-11-11 | Eid Joseph |
SVP,Head Glob. Medical Affairs |
Award↓
Filing footnotes — Stock Option (right to buy) (Direct)
The options vest as follows: 312,500 shares on May 11, 2025, the remaining 2,187,500 shares in series of 42 equal monthly installments commencing May 11, 2025, provided the optionee continues to provide services to the Company. |
Stock Option (right to buy)
|
2,500,000 |
| 2024-11-11 | Eid Joseph |
SVP,Head Glob. Medical Affairs |
Other↑
|
No Securities Owned
|
0 |